Customization: | Available |
---|---|
CAS No.: | 2381089-83-2 |
EINECS: | 200-001-8 |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name: | Retatrutide | Cas No. | 2381089-83-2 |
Purity: | 99% | Sample: | Available |
Package: | Foil Bag | Type: | Powder |
MOQ: | 1 Gram or 1 Box | EINECS: | 203-405-2 |
Transportation: | By Air | Grade Standard | Top Quality |
Sample | Availiable | Shelf Life | 2 Years |
Triple Agonist Mechanism
Retatrutide simultaneously activates GP-1,, and glucagon receptors, offering a multifaceted approach to managing metabolic conditions like type 2 diabetes and obesity.
Improved Blood Sugar Control
By targeting multiple pathways involved in glucose metabolism, Retatrutide helps achieve better glycemic control compared to single or dual agonists.
Significant Weight Loss
Retatrutide has demonstrated strong efficacy in reducing body weight, making it a promising option for individuals with obesity or overweight conditions.
Potential Cardiovascular Benefits
Like other GLP-1 receptor agonists, Retatrutide may offer cardiovascular benefits, such as reducing the risk of heart disease, which is common in people with type 2 diabetes.
Convenient Administration
Retatrutide is administered via subcutaneous injection, typically once weekly, providing a user-friendly treatment option for patients.
Superior Efficacy
Early clinical trials suggest that Retatrutide may outperform existing GP-1 and dual agonists in terms of both glucose control and weight reduction.
Addresses Multiple Metabolic Issues
Its triple-action mechanism not only improves blood sugar levels but also enhances lipid metabolism and energy expenditure, addressing multiple aspects of metabolic health.
Potential for Broader Applications
Retatrutide's unique mechanism may open doors for treating other metabolic disorders beyond type 2 diabetes and obesity.
Well-Tolerated in Clinical Trials
While side effects like nausea and gastrointestinal discomfort are common, Retatrutide has shown a manageable safety profile in clinical studies.
Innovative Therapeutic Option
As a first-in-class triple agonist, Retatrutide represents a significant advancement in the treatment of metabolic diseases, offering hope for patients with unmet medical needs.
Any interest please send us inquiries and tell us how to reach you out, we will reply within 24 hours. | |
Before ordering | Please send what items and what quantity you need |
Send quotation | We will send you a quotation in detail with total |
Payment ways chosen | Please choose one of the payment way you preferred. Our payment ways: Bank wire, Wise, Western Union, Crypto |
After payment | Please offer shipping address after payment for shipment. |
Tracking | We will provide the tracking after goods sent. |
Lead time | About 1-5 working days after payment |
Shipping time | About 8-15 days door to door |
After-sale service | Available always |
Q1: What's your MOQ?